3rd Quarter - Report

NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)

Firm
Client
Income
—
Expenses
$70,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Rare Disease Initiatives. Newborn Screening.. Orphan Drug Act. FDA Modernization. FDA Initiatives.

LobbyistCovered position, as disclosed
MICHAEL JOSEPH BEARD —
KATHRYN LOWELL New —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Pharmacy PHA

Pharmaceutical issues impacting patients with rare diseases. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Patient Experience Data.

LobbyistCovered position, as disclosed
MICHAEL JOSEPH BEARD —
KATHRYN LOWELL New —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Budget/Appropriations BUD

Appropriations impacting patients with rare diseases. National Institutes of Health (NIH) NCATS Appropriations. Legislation on Accepting User Fees during a Lapse in Government Funding.

LobbyistCovered position, as disclosed
MICHAEL JOSEPH BEARD —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.